Trial Profile
A Phase 2/3, Randomized, Double-Blind, Placebo-Controlled Study of Abiraterone Acetate Plus Prednisone With or Without Abemaciclib in Patients With Metastatic Castration-Resistant Prostate Cancer
Status:
Active, no longer recruiting
Phase of Trial:
Phase II/III
Latest Information Update: 21 Feb 2024
Price :
$35
*
At a glance
- Drugs Abemaciclib (Primary) ; Abiraterone acetate; Prednisolone; Prednisone
- Indications Adenocarcinoma; Prostate cancer
- Focus Therapeutic Use
- Acronyms CYCLONE 2
- Sponsors Eli Lilly and Company
- 06 Dec 2023 Planned primary completion date changed from 14 Nov 2023 to 2 Jan 2024.
- 20 Oct 2023 Planned primary completion date changed from 3 Nov 2023 to 14 Nov 2023.
- 28 Apr 2023 Status changed from recruiting to active, no longer recruiting.